James Peter Hamilton, M.D.

Headshot of James Peter Hamilton
  • Director of Hepatology
  • Associate Professor of Medicine


Acute Viral Hepatitis, Alcoholic Liver Disease, Alpha 1 Antitrypsin (AAT) Deficiency, Ascites, Autoimmune Hepatitis, Benign Liver Lesions, Bile Duct Disease, Cholangiocarcinoma, Cholestatic Liver Diseases of Childhood, Cirrhosis, Elevated Liver Tests, Esophageal varices (Enlarged Veins), Fatty Liver, Gastroenterology, Hemangiomas, Hemochromatosis, Hepatic Adenoma, Hepatic Encephalopathy, Hepatitis, Hepatocellular Carcinoma, Hepatomegaly (Enlarged Liver), Jaundice, Liver Cancer, Liver Cysts, Liver Disease, Liver Injury, Liver Mass, Liver Test Abnormalities, Liver Transplant, Liver Transplant Evaluation, Liver Tumors, Nonalcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis (NASH), Primary Biliary Cholangitis, Sclerosing Cholangitis, Wilson Disease ...read more

Research Interests

Wilson Disease: Copper homeostasis and regulation of lipid metabolism and liver injury. Pathogenesis of Liver fibrosis and cancer; Early detection biomarker discovery for hepatocellular carcinoma ...read more

Request an Appointment

Insurance Information

Main Phone

Outside of Maryland & Washington D.C.

Request Appointment

International Patients

Request Appointment


Johns Hopkins Medicine - Green Spring Station

Appointment Phone: 410-933-7495
2360 W. Joppa Road
Joppa Concourse Suite 205
Lutherville, MD 21093
Johns Hopkins Medicine - Green Spring Station - Google Maps

The Johns Hopkins Hospital (Main Entrance)

Appointment Phone: 410-933-7495
1800 Orleans St.
Sheikh Zayed Tower
Baltimore, MD 21287
Phone: 410-614-3530 | Fax: 410-955-9677
The Johns Hopkins Hospital (Main Entrance) - Google Maps


Dr. Hamilton is an Associate Professor of Medicine in the Division of Gastroenterology and Hepatology. He is Director of Hepatology for Johns Hopkins Medicine.

His clinical specialties include Wilson Disease, Cystic Fibrosis related liver disease, liver transplantation, hepatocellular carcinoma, cirrhosis, portal hypertension, acute and chronic viral, non-alcoholic fatty liver disease (NASH), autoimmune, and cholestatic liver disease. 

His research interests include the copper homeostasis and its regulation of lipid metabolism and liver injury, the fundamental mechanisms regulating liver fibrosis, and the molecular genetics of hepatocellular carcinoma and early detection biomarkers. 

Dr. Hamilton is a 2005 recipient of the National Institutes of Health/ National Research Scholar Award for gastroenterology and hepatology.

...read more


  • Director of Hepatology
  • Associate Professor of Medicine

Departments / Divisions

Centers & Institutes



  • MD; Medicine; University of Maryland School of Medicine (2000)


  • Internal Medicine; McGaw Medical Center of Northwestern University (2003)


  • Gastroenterology; Johns Hopkins University School of Medicine (2007)
  • Gastroenterology; University of Maryland Medical Center (2006)

Board Certifications

  • American Board of Internal Medicine (Gastroenterology) (2017)
  • American Board of Internal Medicine (Transplant Hepatology) (2008)

Research & Publications

Clinical Trials

A Phase 3, Double-Blind Randomized, Long-term, Placebo-controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid (OCA) in subjects with Non-Alcoholic Steatohepatitis (REGENERATE)

A Phase 2, Double-blind, Randomized, Placebo-controlled, Dose-finding Study to Evaluate the Safety, Tolerability and Efficacy of Volixibat Potassium, an Apical Sodium-Dependent Bile Acid Transporter Inhibitor (ASBTi) in Adults with Nonalcoholic Steatohepatitis (NASH)

Sofusbuvir and Ledipasvir in HIV/HCV Coinfected Pre and Post Liver Transplant

A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients with Hepatocellular Carcinoma (HCC)

Selected Publications

Hamilton JP, Potter JJ, Koganti L, Meltzer SJ, Mezey E. Effects of Vitamin D stimulation of Thioredoxin Interacting Protein in hepatocellular carcinoma. Hepatol Res. 2014; 44(13): 1357-66. PMID: 24451003

Karthikeyan S, Potter JJ, Geschwind JF, Sur S, Hamilton JP, Vogelstein B, Kinzler KW, Mezey E, Gaganpathy-Kanniappan S. Deregulation of energy Metabolism Promotes Antfibrotic Effects in Human Hepatic Stellate Cells and Prevents Liver Fibrosis in a Mouse Model. Biochem Biophys Res Comm 2016; 469(3): 463-9. PMID: 26525850

Hamilton JP, Koganti L, Muchenditsi A, Pendyala VS, Huso D, Hankin J, Murphy RC, Huster D, Merle U, Mangels C, Yang N, Potter JJ, Mezey E, Lutsenko S. Activation of LXR/RXR Pathway Ameliorates Liver disease in ATP7b-/- (Wilson disease) mice. Hepatology 2016; 63(6): 1828-41. PMID: 26679751

Oh Y, Park O, Swierczewska M, Hamilton JP, Park JS, Kim TH, Lim SH, Eom H, Jo DG, Lee CE, Kechrid R, Mastorakos P, Zhang C, Hahn SK, Jeon OC, Byun Y, Km K, Hanes J, Lee KC, Pomper MG, Gao B, Lee S. Systemic PEGylated TRAIL treatment ameliorates liver cirrhosis in rats by eliminating hepatic stellate cells. Hepatology 2016; 64(1): 209-23. PMID: 26710118

Contact for Research Inquiries

720 Rutland Ave
Ross 921
Baltimore, MD 21205 map

Activities & Honors


  • Research Fellowship, NRSA
  • Top Doctor, Baltimore Magazine, 2018 - 2018
  • Top Doctor, Baltimore Magazine, 2019 - 2019
  • Top Doctor, Baltimore Magazine, 2020 - 2020


  • AGA
Is this you? Edit Profile
back to top button